Clinical Trials
23 trialsNCT06966700 2026-06-01
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT05989828 2026-05-19
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
University of Southern California
Phase 1 Recruiting
NCT05492682 2026-05-12
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase 1 Recruiting
NCT04771871 2026-05-07
TARMAC
University College Hospital, Ibadan
Phase 2 Recruiting
NCT06347068 2026-04-22
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT07486089 2026-03-20
DUAL-NK-BC
Beijing Biotech
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT06318897 2026-03-04
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT06690840 2026-01-05
AZALEA
European Institute of Oncology
Phase 2 Recruiting
NCT07178171 2025-11-24
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Xijing Hospital
Phase 1 Recruiting
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT06245889 2025-09-23
NeoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05020860 2025-02-27
RESPONSE
Baylor Breast Care Center
Phase 2 Recruiting
NCT06532812 2024-11-12
BAH249
Essen Biotech
Phase 1/2 Recruiting
NCT04282044 2024-02-08
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
Phase 1 Recruiting
NCT05916755 2023-06-23
PORTRAIT
Vall d'Hebron Institute of Oncology
Recruiting
NCT05447702 2023-05-22
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Phase 2 Recruiting
NCT04437160 2020-06-18
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
ChineseAMS
Phase 2 Recruiting